Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.08
SNN's Cash to Debt is ranked lower than
94% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. SNN: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
SNN' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.15 Max: 2.58
Current: 0.08
0.06
2.58
Equity to Asset 0.56
SNN's Equity to Asset is ranked lower than
63% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. SNN: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
SNN' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.53 Max: 0.7
Current: 0.56
0.34
0.7
Interest Coverage 17.45
SNN's Interest Coverage is ranked lower than
61% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 38.74 vs. SNN: 17.45 )
Ranked among companies with meaningful Interest Coverage only.
SNN' s Interest Coverage Range Over the Past 10 Years
Min: 8.87  Med: 36.26 Max: 81
Current: 17.45
8.87
81
F-Score: 4
Z-Score: 4.78
M-Score: -2.70
WACC vs ROIC
6.61%
8.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 16.16
SNN's Operating margin (%) is ranked higher than
85% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.65 vs. SNN: 16.16 )
Ranked among companies with meaningful Operating margin (%) only.
SNN' s Operating margin (%) Range Over the Past 10 Years
Min: 13.55  Med: 18.90 Max: 23.22
Current: 16.16
13.55
23.22
Net-margin (%) 10.72
SNN's Net-margin (%) is ranked higher than
79% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. SNN: 10.72 )
Ranked among companies with meaningful Net-margin (%) only.
SNN' s Net-margin (%) Range Over the Past 10 Years
Min: 8.85  Med: 12.65 Max: 26.81
Current: 10.72
8.85
26.81
ROE (%) 11.92
SNN's ROE (%) is ranked higher than
76% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. SNN: 11.92 )
Ranked among companies with meaningful ROE (%) only.
SNN' s ROE (%) Range Over the Past 10 Years
Min: 10.47  Med: 19.91 Max: 39.32
Current: 11.92
10.47
39.32
ROA (%) 6.51
SNN's ROA (%) is ranked higher than
74% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.01 vs. SNN: 6.51 )
Ranked among companies with meaningful ROA (%) only.
SNN' s ROA (%) Range Over the Past 10 Years
Min: 5.79  Med: 9.82 Max: 22.64
Current: 6.51
5.79
22.64
ROC (Joel Greenblatt) (%) 34.57
SNN's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 4.86 vs. SNN: 34.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 30.86  Med: 43.07 Max: 56.89
Current: 34.57
30.86
56.89
Revenue Growth (3Y)(%) 6.60
SNN's Revenue Growth (3Y)(%) is ranked higher than
60% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. SNN: 6.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.6  Med: 6.60 Max: 54.6
Current: 6.6
-19.6
54.6
EBITDA Growth (3Y)(%) -5.50
SNN's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SNN: -5.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.8  Med: 9.00 Max: 52.8
Current: -5.5
-10.8
52.8
EPS Growth (3Y)(%) -15.30
SNN's EPS Growth (3Y)(%) is ranked lower than
75% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SNN: -15.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.1  Med: 13.40 Max: 57
Current: -15.3
-24.1
57
» SNN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SNN Guru Trades in Q2 2015

Steven Cohen 50,600 sh (New)
John Hussman 15,000 sh (unchged)
Pioneer Investments 84,570 sh (unchged)
Eric Mindich 502,000 sh (unchged)
Ken Fisher 2,083,106 sh (-9.42%)
David Dreman 103,704 sh (-11.73%)
Jim Simons 144,250 sh (-53.47%)
Mario Gabelli 6,375 sh (-75.36%)
» More
Q3 2015

SNN Guru Trades in Q3 2015

Jim Simons 195,250 sh (+35.36%)
Eric Mindich 567,193 sh (+12.99%)
Mario Gabelli 6,975 sh (+9.41%)
Ken Fisher 2,190,240 sh (+5.14%)
Pioneer Investments 84,690 sh (+0.14%)
John Hussman 15,000 sh (unchged)
David Dreman Sold Out
Steven Cohen 23,000 sh (-54.55%)
» More
Q4 2015

SNN Guru Trades in Q4 2015

Steven Cohen 70,600 sh (+206.96%)
Jim Simons 302,300 sh (+54.83%)
Ken Fisher 2,207,255 sh (+0.78%)
John Hussman Sold Out
Eric Mindich Sold Out
Pioneer Investments Sold Out
Mario Gabelli 6,775 sh (-2.87%)
» More
Q1 2016

SNN Guru Trades in Q1 2016

Jim Simons 1,111,500 sh (+267.68%)
Ken Fisher 2,417,325 sh (+9.52%)
Steven Cohen Sold Out
Mario Gabelli 6,675 sh (-1.48%)
» More
» Details

Insider Trades

Latest Guru Trades with SNN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:VAR, OTCPK:SONVY, NYSE:TFX, NAS:ALGN, NYSE:STJ, OTCPK:SDMHF, NYSE:EW, OTCPK:CHEOY, OTCPK:WILYY, NAS:ABMD, NYSE:ZBH, OTCPK:FSPKF, NAS:ISRG, NAS:IART, NAS:NUVA, OTCPK:EKTAF, NAS:MASI, NAS:LIVN, OTCPK:NHNKY, OTCPK:SHWGF » details
Traded in other countries:NPWA.Germany, SN..UK, SNNUF.USA,
Smith & Nephew PLC develops, manufactures, markets and sells medical devices in the sectors of Advanced Surgical Devices and Advanced Wound Management.

Smith & Nephew PLC was incorporated on February 17, 1937. The Company develops, manufactures, markets and sells medical devices. The Company is organized into business segments namely Advanced Surgical Devices and Advanced Wound Management. The Advanced Surgical Devices offers Orthopaedic Reconstruction which includes Hip Implants, Knee Implants and ancillary products, Trauma & Extremities consisting of internal and external devices used in the stabilisation of severe fractures and deformity correction procedures, Sports Medicine Joint Repair, offers surgeons a various instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, Arthroscopy Enabling Technologies offers healthcare providers various technologies such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources and monitors to assist with visualisation inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. Trauma & Extremities consists of internal and external devices used in the stabilisation of severe fractures and deformity correction procedures. Other Surgical businesses include gynaecological instrumentation as well as various products and technologies to assist in surgical treatment of the ear, nose and throat. Knee Implants, offers products for specialised knee replacement procedures and Hip Implants, offers specialist products for reconstruction of the hip joint. The Advanced Wound Management segment offers Advanced Wound Care, which includes products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns and post-operative wounds, Advanced Wound Devices, consists of traditional and single-use Negative Pressure Wound Therapy and hydrosurgery systems, Advanced Wound Bioactives includes biologics and other bioactive technologies that provide approaches to debridement and dermal repair/regeneration.

Ratios

vs
industry
vs
history
P/E(ttm) 33.59
SNN's P/E(ttm) is ranked lower than
64% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 28.34 vs. SNN: 33.59 )
Ranked among companies with meaningful P/E(ttm) only.
SNN' s P/E(ttm) Range Over the Past 10 Years
Min: 10.23  Med: 19.80 Max: 71.79
Current: 33.59
10.23
71.79
Forward P/E 19.16
SNN's Forward P/E is ranked higher than
78% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 24.63 vs. SNN: 19.16 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.59
SNN's PE(NRI) is ranked lower than
63% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 28.88 vs. SNN: 33.59 )
Ranked among companies with meaningful PE(NRI) only.
SNN' s PE(NRI) Range Over the Past 10 Years
Min: 11.57  Med: 23.21 Max: 71.53
Current: 33.59
11.57
71.53
P/B 4.30
SNN's P/B is ranked lower than
64% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. SNN: 4.30 )
Ranked among companies with meaningful P/B only.
SNN' s P/B Range Over the Past 10 Years
Min: 2.32  Med: 3.87 Max: 7.12
Current: 4.3
2.32
7.12
P/S 16.91
SNN's P/S is ranked lower than
88% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. SNN: 16.91 )
Ranked among companies with meaningful P/S only.
SNN' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 2.87 Max: 17.82
Current: 16.91
1.67
17.82
PFCF 119.52
SNN's PFCF is ranked lower than
95% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 31.08 vs. SNN: 119.52 )
Ranked among companies with meaningful PFCF only.
SNN' s PFCF Range Over the Past 10 Years
Min: 12.85  Med: 32.14 Max: 153.64
Current: 119.52
12.85
153.64
POCF 92.07
SNN's POCF is ranked lower than
98% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 20.58 vs. SNN: 92.07 )
Ranked among companies with meaningful POCF only.
SNN' s POCF Range Over the Past 10 Years
Min: 8.25  Med: 17.44 Max: 97.04
Current: 92.07
8.25
97.04
EV-to-EBIT 93.62
SNN's EV-to-EBIT is ranked lower than
88% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. SNN: 93.62 )
Ranked among companies with meaningful EV-to-EBIT only.
SNN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 15.80 Max: 41.5
Current: 93.62
7.5
41.5
EV-to-EBITDA 61.20
SNN's EV-to-EBITDA is ranked lower than
90% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 18.09 vs. SNN: 61.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.8  Med: 11.30 Max: 29.8
Current: 61.2
5.8
29.8
Shiller P/E 32.69
SNN's Shiller P/E is ranked higher than
62% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 41.87 vs. SNN: 32.69 )
Ranked among companies with meaningful Shiller P/E only.
SNN' s Shiller P/E Range Over the Past 10 Years
Min: 19.06  Med: 28.81 Max: 59.5
Current: 32.69
19.06
59.5
Current Ratio 1.84
SNN's Current Ratio is ranked lower than
71% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.83 vs. SNN: 1.84 )
Ranked among companies with meaningful Current Ratio only.
SNN' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.76 Max: 2.42
Current: 1.84
0.84
2.42
Quick Ratio 0.94
SNN's Quick Ratio is ranked lower than
82% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. SNN: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
SNN' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.99 Max: 1.35
Current: 0.94
0.47
1.35
Days Inventory 385.01
SNN's Days Inventory is ranked lower than
91% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 134.88 vs. SNN: 385.01 )
Ranked among companies with meaningful Days Inventory only.
SNN' s Days Inventory Range Over the Past 10 Years
Min: 253.48  Med: 311.87 Max: 374.7
Current: 385.01
253.48
374.7
Days Sales Outstanding 80.68
SNN's Days Sales Outstanding is ranked lower than
60% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 68.74 vs. SNN: 80.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 73.96  Med: 85.70 Max: 94.34
Current: 80.68
73.96
94.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.85
SNN's Dividend Yield is ranked higher than
63% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.58 vs. SNN: 1.85 )
Ranked among companies with meaningful Dividend Yield only.
SNN' s Dividend Yield Range Over the Past 10 Years
Min: 0.84  Med: 1.41 Max: 2.28
Current: 1.85
0.84
2.28
Dividend Payout 0.67
SNN's Dividend Payout is ranked lower than
80% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 0.34 vs. SNN: 0.67 )
Ranked among companies with meaningful Dividend Payout only.
SNN' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.39 Max: 10.82
Current: 0.67
0.22
10.82
Dividend Growth (3y) 14.70
SNN's Dividend Growth (3y) is ranked higher than
63% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. SNN: 14.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -54  Med: 11.00 Max: 19.6
Current: 14.7
-54
19.6
Forward Dividend Yield 2.28
SNN's Forward Dividend Yield is ranked higher than
72% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. SNN: 2.28 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.87
SNN's Yield on cost (5-Year) is ranked higher than
83% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. SNN: 3.87 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.76  Med: 2.95 Max: 4.77
Current: 3.87
1.76
4.77
3-Year Average Share Buyback Ratio 1.30
SNN's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: -3.30 vs. SNN: 1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: -0.30 Max: 5.8
Current: 1.3
-2.5
5.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 37.67
SNN's Price/Tangible Book is ranked lower than
96% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. SNN: 37.67 )
Ranked among companies with meaningful Price/Tangible Book only.
SNN' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.62  Med: 13.12 Max: 66.37
Current: 37.67
4.62
66.37
Price/Projected FCF 2.17
SNN's Price/Projected FCF is ranked higher than
50% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. SNN: 2.17 )
Ranked among companies with meaningful Price/Projected FCF only.
SNN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.04  Med: 2.11 Max: 10.72
Current: 2.17
1.04
10.72
Price/Median PS Value 5.90
SNN's Price/Median PS Value is ranked lower than
98% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. SNN: 5.90 )
Ranked among companies with meaningful Price/Median PS Value only.
SNN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.17 Max: 5.73
Current: 5.9
0.65
5.73
Price/Graham Number 8.28
SNN's Price/Graham Number is ranked lower than
90% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. SNN: 8.28 )
Ranked among companies with meaningful Price/Graham Number only.
SNN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.93  Med: 4.40 Max: 9.9
Current: 8.28
1.93
9.9
Earnings Yield (Greenblatt) (%) 1.10
SNN's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. SNN: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 6.30 Max: 13.4
Current: 1.1
2.4
13.4
Forward Rate of Return (Yacktman) (%) -5.81
SNN's Forward Rate of Return (Yacktman) (%) is ranked lower than
81% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 7.42 vs. SNN: -5.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.7  Med: 24.20 Max: 66.7
Current: -5.81
-6.7
66.7

More Statistics

Revenue (TTM) (Mil) $4,567
EPS (TTM) $ 1.14
Beta0.73
Short Percentage of Float0.31%
52-Week Range $30.23 - 37.84
Shares Outstanding (Mil)457.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4,810 5,005 5,229
EPS ($) 1.84 1.84 2.17
EPS w/o NRI ($) 1.84 1.84 2.17
EPS Growth Rate
(3Y to 5Y Estimate)
17.79%
Dividends Per Share ($) 0.65 0.69 0.79
» More Articles for SNN

Headlines

Articles On GuruFocus.com
Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
3 Dividend Kings From The U.K. I Love To Buy Aug 21 2014 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 
5 Highly Predictable Mid-/Large-Caps with ROC Over 15% Apr 21 2012 
The Best Dividends on April 18, 2012 Apr 18 2012 
5 Healthcare Stocks to Consider Today Mar 21 2012 
Stryker Corp. (SYK) Dividend Stock Analysis Dec 16 2011 

More From Other Websites
Smith & Nephew’s NAVIO™ Surgical System achieves robotics-assisted milestone for total knee... Jul 28 2016
8:30 am Smith & Nephew reported H1 EPS of $0.27 vs $0.38 Capital IQ consensus; revs +2% YoY to... Jul 28 2016
Smith & Nephew's NAVIO™ Surgical System achieves robotics-assisted milestone for total knee... Jul 28 2016
FTSE edges down from 1-year high, earnings weigh Jul 28 2016
Weak China sales drag down Smith & Nephew profits Jul 28 2016
BUZZ-Smith & Nephew: Bottom of the FTSE after weak H1 Jul 28 2016
Second Quarter Trading and First Half 2016 Results Jul 28 2016
Smith & Nephew buoyed by sports medicine but China weak Jul 28 2016
Smith & Nephew buoyed by sports medicine but China weak Jul 28 2016
ETF’s with exposure to Smith & Nephew Plc : July 18, 2016 Jul 18 2016
Smith & Nephew extends its Wound Care Academy to the Kingdom of Saudi Arabia Jul 16 2016
Timing of Smith & Nephew Second Quarter Trading and First Half 2016 Results Jul 13 2016
Smith & Nephew Plc :SNN-US: Earnings Analysis: For the six months ended December 31, 2015 : July 11,... Jul 11 2016
CFO to leave Smith & Nephew in early 2017 Jul 11 2016
New protocol including the use of ALLEVYN™ LIFE reduces hospital-acquired pressure ulcers by 69%... Jul 06 2016
New protocol including the use of ALLEVYN™ LIFE reduces hospital-acquired pressure ulcers by 69%... Jul 06 2016
New protocol including the use of ALLEVYN™ LIFE reduces hospital-acquired pressure ulcers by 69%... Jul 06 2016
Notification regarding the litigation initiated by Greenpeace CEE Romania Foundation and the... Jun 24 2016
Current report regarding the completion of works related to the planned outage of Cernavoda NPP Unit... Jun 24 2016
Current report: Event at Cernavoda NPP Unit 4 Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)